Evidence map›Paper›PMID 39791266›Full record

ArticleCurrent protocols2025

Modeling Malignant Mesothelioma in Genetically Engineered Mice.

Yuwaraj Kadariya, Eleonora Sementino, Xiang Hua, Dietmar J Kappes, Joseph R Testa

Abstract read
In one paragraph

Article in Current protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuwaraj KadariyaCancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Eleonora SementinoCancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Xiang HuaNuclear Dynamics and Cancer Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Dietmar J KappesNuclear Dynamics and Cancer Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Joseph R TestaCancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.ORCID https://orcid.org/0000-0003-1301-5175

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI DAVID L. WIEST · 1985 to 2026
$138.8M
Environmental Science Project 3 - Social Determinants of Risk and Attitudes AboutP42ES023720 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI BLAIR, IAN ALEXANDER · 2014 to 2018
$11.3M
Pathogenesis of Malignant Mesothelioma by the Human Polycomb Complex BAP1-ASXLR01CA175691 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI RAUSCHER III, FRANK JOSEPH, TESTA, JOSEPH R. · 2014 to 2018
$2.7M
MOLECULAR GENETIC ALTERATIONS IN MALIGNANT MESOTHELIOMAR01CA045745 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI TESTA, JOSEPH R. · 1987 to 2006
$1.8M
Role of the Parkinson's susceptibility gene LRRK2 in NFAT-mediated malignant mesothelioma tumorigenesisR03CA280410 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI TESTA, JOSEPH R. · 2023 to 2024
$188k
CLC NIH HHS 75N90019D00022NCI NIH HHS P30 CA006927NCI NIH HHS R01 CA045745NCI NIH HHS R01 CA175691NCI NIH HHS R03 CA280410NIEHS NIH HHS P42 ES023720NIOSH CDC HHS U24 OH009077ORFDO NIH HHS 75N99019D00022
6 · The paper itself

Abstract

Mesothelioma is a lethal cancer of the serosal lining of the body cavities. Risk factors include environmental and genetic factors. Asbestos exposure is considered the principal environmental risk factor, but other carcinogenic mineral fibers, such as erionite, also have a causal role. Pathogenic germline (heritable) mutations of specific genes, especially BAP1, are thought to predispose the individual to mesothelioma in about 10% of cases. Somatic mutations and deletions of specific tumor suppressor genes, particularly BAP1, CDKN2A/B, and NF2, occur frequently in human mesothelioma, and asbestos-exposed mice with heterozygous deletions of any one of these genes have been shown to develop mesothelioma more often and at an accelerated rate than in control animals. Autochthonous mesothelioma mouse models, which are genetically engineered to carry multiple genetic lesions matching those observed in the human disease counterpart, closely resemble the disease phenotype and the extensive inflammatory responses that characterize human mesothelioma. Because autochthonous mice do not require asbestos exposure and form tumors rapidly, these models are invaluable for assessing novel therapeutic strategies in an immunocompetent setting. The overlapping genetic, epigenetic, and immune environments of the tumors observed in these genetically engineered mouse models (GEMMs) and human primary mesothelioma specimens support the clinical relevance of these preclinical models. This article presents protocols for studies of asbestos-induced mesothelioma in GEMMs and non-carcinogenic conditional knockout models of mesothelioma, including an example of a preclinical application. These models are invaluable for understanding the biological underpinnings of mesothelioma and for testing new therapeutics and chemoprevention or interception agents. © 2025 Wiley Periodicals LLC. Basic Protocol 1: Generation of a genetically engineered mouse model (GEMM) with a germline Bap1 knockout allele Basic Protocol 2: Generation of GEMMs with germline Bap1 knock-in alleles Basic Protocol 3: Asbestos carcinogenicity investigations with GEMMs Basic Protocol 4: Preclinical chemoprevention and chemotherapy studies using a GEMM with asbestos-induced mesothelioma Basic Protocol 5: Generation of a GEMM with conditional knockout of Bap1 Basic Protocol 6: Generation of a conditional knockout model of mesothelioma.

Indexed as

Disease Models, AnimalLung NeoplasmsMesotheliomaMesothelioma, MalignantAnimalsAsbestosGenetic EngineeringHumansMiceMice, TransgenicAsbestosasbestos carcinogenicityconditional knockout miceintraperitoneal tumorsintrapleural tumorsmesothelioma

Identifiers

PMID39791266
PMCPMC11737608

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.